Behavioural patterns in allergic rhinitis medication in Europe
ǂa ǂstudy using 28 MASK-air® real-world data
Povzetek
Background. Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data. Methods. We analysed 2015-2020 MASK-air® European data. We compared days under no medication, monotherapy, and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms (“VAS Global Symptoms”) and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within one year. Results. We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy, and 38,315 (17.3%) under co-medication. The median “VAS Global Symptoms” was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p<0.001). Medication use peaked during the spring, with similar patterns across different European regions (defined geographically or by Google Trends). Oral H1-antihistamines were the most common medication in single and co-medication. Each patient reported using an annual average of 2.7 drugs, with 80% reporting two or more. Conclusions. AR medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR), and that co-medication use is driven by symptom severity.
Ključne besede
antihistamines;behavioural patterns;medication patterns;real-world data;
Podatki
| Jezik: | Angleški jezik |
|---|---|
| Leto izida: | 2022 |
| Tipologija: | 1.01 - Izvirni znanstveni članek |
| Založnik: | John Wiley & Sons |
| UDK: | 616-097 |
| COBISS: |
100821507
|
| ISSN: | 1398-9995 |
| Št. ogledov: | 153 |
| Št. prenosov: | 41 |
| Ocena: | 0 (0 glasov) |
| Metapodatki: |
|
Ostali podatki
| Sekundarne ključne besede: | antihistaminiki;vedenjski vzorci;vzorci zdravljenja;podatki iz resničnega življenja;Asthma;Drug therapy;Rhinitis;Rhinitis, allergic;Visual analogue scale;Histamine antagonists;Astma;Terapija z zdravili;Rinitis;Alergijski rinitis;Vizualna analogna lestvica;Histaminski antagonisti; |
|---|---|
| Komentar vira: | Nasl. z nasl. zaslona; Soavtorica iz Slovenije: Mihaela Zidarn; Opis vira z dne 14. 3. 2022; |
| Strani: | str. 2699-2711 |
| Letnik: | ǂVol. ǂ77 |
| Zvezek: | ǂiss. ǂ9 |
| Čas izdaje: | Sept. 2022 |
| DOI: | 10.1111/all.15275 |
| ID: | 14751684 |
Priporočena dela:
Behavioural patterns in allergic rhinitis medication in Europe
2022,
ǂa ǂstudy using 28 MASK-air® real-world data
ARIA digital anamorphosis
2021,
digital transformation of health and care in airway diseases from research to practice
Allergic rhinitis and its impact on asthma (ARIA) phase 4 (2018)
2019,
change management in allergic rhinitis and asthma multimorbidity using mobile technology
ARIA pharmacy 2018 "Allergic rhinitis care pathways for community pharmacy"
2019,
ni podatka o podnaslovu
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN)
2021,
ǂa ǂretrospective analysis of patients treated through an access program